Cytek Biosciences to present at the 42nd Annual J.P. Morgan Healthcare Conference
29 December 2023 - 8:05AM
Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis
solutions company, today announced the company will be
participating in the upcoming 42nd Annual J.P. Morgan Healthcare
Conference in San Francisco, CA.
CEO Dr. Wenbin Jiang is scheduled to present and participate in
a Q&A session on Thursday, January 11, at 8:15 a.m. Pacific
Time / 11:15 a.m. Eastern Time. Interested parties may access a
live and archived webcast of the presentation on the “Investors”
section of the company website at: investors.cytekbio.com.
About Cytek Biosciences, Inc.
Cytek Biosciences (Nasdaq: CTKB) is a leading cell analysis
solutions company advancing the next generation of cell analysis
tools by delivering high-resolution, high-content and
high-sensitivity cell analysis utilizing its patented Full Spectrum
Profiling™ (FSP™) technology. Cytek’s novel approach harnesses the
power of information within the entire spectrum of a fluorescent
signal to achieve a higher level of multiplexing with precision and
sensitivity. Cytek’s FSP platform includes its core instruments,
the Cytek Aurora™ and Northern Lights™ systems; its cell sorter,
the Cytek Aurora™ CS; the flow cytometer and imaging products under
the Amnis® and Guava® brands; and reagents, software and
services to provide a comprehensive and integrated suite of
solutions for its customers. Cytek is headquartered in Fremont,
California with offices and distribution channels across the globe.
More information about the company and its products is available
at www.cytekbio.com.
Cytek’s products are for research use only and not for use in
diagnostic procedures (other than Cytek’s Northern Lights-CLC
system and certain reagents, which are available for clinical use
in China and the European Union).
Cytek, Full Spectrum Profiling, FSP, Cytek Aurora, Northern
Lights, Cytek Orion, SpectroPrep, Amnis and Guava are trademarks of
Cytek Biosciences, Inc.
In addition to filings with the Securities and Exchange
Commission (SEC), press releases, public conference calls and
webcasts, Cytek uses its website (www.cytekbio.com), LinkedIn
page and X (formerly Twitter) account as channels of
distribution of information about its company, products, planned
financial and other announcements, attendance at upcoming investor
and industry conferences and other matters. Such information may be
deemed material information and Cytek may use these channels to
comply with its disclosure obligations under Regulation FD.
Therefore, investors should monitor Cytek’s website, LinkedIn page,
and X account in addition to following its SEC filings, news
releases, public conference calls and webcasts.
Media Contact:Stephanie OlsenLages &
Associates(949) 453-8080stephanie@lages.com
Investor Contact:Paul GoodsonHead of Investor
RelationsCytek Biosciencespgoodson@cytekbio.com
Cytek Biosciences (NASDAQ:CTKB)
Historical Stock Chart
From May 2024 to Jun 2024
Cytek Biosciences (NASDAQ:CTKB)
Historical Stock Chart
From Jun 2023 to Jun 2024